Mantle in Medical Technology

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... affecting the immune system, such as DLBCL, mantle cell lymphoma and follicular lymphoma(2). Up to ... lymphoma, Hodgkin's disease, follicular lymphoma, mantle cell lymphoma, DLBCL and small lymphocytic ... disease (53% ORR), follicular lymphoma (50% ORR), mantle cell lymphoma (32% ORR), DLBCL (30% ORR) and ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated ... was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated ... was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and ...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

... of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to ... employed in patients with indolent B-cell and mantle cell lymphomas, but resistance to treatment ... 66 patients with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... market leader in relapsed multiple myeloma and mantle cell lymphoma (MCL). "These data, as well as ... indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, ...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of ... (ASCO) in Chicago. "Relapsed/refractory mantle cell lymphoma is extremely difficult to treat, ... 2 studies of temsirolimus in relapsed/refractory mantle cell lymphoma and indicate that mTOR inhibition ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... only drug approved for the treatment of relapsed mantle cell lymphoma. "VELCADE based therapies ... therapy for patients with previously treated mantle cell lymphoma (MCL), the most aggressive form of ... About Non-Hodgkin's Lymphoma (NHL) and mantle Cell Lymphoma (MCL) NHL is the most common ...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

... Demonstrates Activity in Multiple Myeloma and mantle Cell Lymphoma SOUTH SAN FRANCISCO, Calif., ... of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in ... between SNS-032's mechanism and its activity in mantle cell ....

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

... the only approved therapy in previously treated mantle cell lymphoma (MCL), the most aggressive form of ... About Non-Hodgkin's Lymphoma and mantle Cell Lymphoma NHL is the most common ... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

... therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... of VELCADE as a Single-Agent: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were ...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... of VELCADE as a single-agent: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were ...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... medical conditions. Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were ...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

... has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma. Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma. Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... LBH589 ), showing early activity across a broad range of cancers, including acute myeloid leukemia, cutaneous t-cell lymphoma, multiple myeloma and mantle cell lymphoma The most significant presentations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) will include: ...

University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society

... better. Once the most promising combination is identified, Dr. Friedberg will pursue a clinical trial enrolling patients with relapsed indolent and mantle cell NHL. "To effectively eradicate cancers we must learn which molecules cause them and then develop new treatments that kill cancer cells without ...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... blinatumomab for certain types of indolent B cell lymphoma. Blinatumomab also received orphan drug designation from the European Medicines Agency for mantle cell lymphoma and chronic lymphocytic leukemia. Blinatumomab specifically targets the CD19 antigen, which is present on B cells and B cell-derived ...

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

... Non-Evaluable because of withdrawal due to adverse events or non-compliance with protocol ** Other NHL patients include 10 with SLL/CLL, 8 with mantle Cell Lymphoma (MCL), 3 with MALT, and 1 with Lymphoplasmacystic At two months of therapy, 53 of the 59 patients were evaluated. Five patients ...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

... -- SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors Abstract #756 8:00 a.m. - 12:00 p.m. Exhibit ...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

... and therapy. Median age of the patients treated was 59.6 years (range 19.8 to 78.9 years). Lymphoma histologies included diffuse B cell (n=20), mantle cell (n=13), follicular (n=4) and transformed (n=4). Median tumor bulk prior to treatment was 3.1cm; median number of prior therapies was 2 with ...

Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

... Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell NHLs include mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas related to ...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

... data analysis. In addition, Cephalon has completed a phase 2 study with TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. Cephalon plans to submit a new drug application (NDA) for TREANDA by the end of 2007 for the treatment of patients with indolent NHL whose ...

TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil

... during the ASH annual meeting. In addition, Cephalon has studied TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. Cephalon plans to submit an NDA for TREANDA by the end of 2007 as a single agent for the treatment of patients with indolent NHL whose ...

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

... and malignant B-cells in diseases such as CLL, acute lymphoblastic leukemia, follicular non-Hodgkins lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma. The IND for the treatment of CLL is for an open-label, multi-dose, dose-escalation Phase I clinical trial for cancer that is ...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

... was seen for the first time in patients with mantle cell lymphoma, a rare, aggressive form of ... newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL). Medical databases (Cochrane ... and Overall Survival in Patients With Indolent or mantle Cell Lymphoma: A Systematic Review and ...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

... (GX15-070), induced cell death in vitro in mantle Cell Lymphoma (MCL) cell lines and primary cells ... in clinical and biological activity. About mantle Cell Lymphoma (MCL) mantle cell lymphoma (MCL) belongs to a group of ...

Nereus Pharmaceuticals to Present Data at the American Association for Cancer Research 2007 Annual Meeting

... #1454: A novel proteasome inhibitor, NPI-0052 is active in Hodgkin and mantle cell lymphoma cell lines Buglio Daniela, Georgios Georgakis, Victor ... after bortezomib was successfully developed to treat multiple myeloma and mantle cell lymphoma. Preclinical studies indicate NPI-0052 is active against ...

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

... Cancer Center, focuses on Atiprimod's ability to inhibit proliferation of mantle cell lymphoma (MCL) cells in vitro and to inhibit growth of MCL tumors in ... and is titled: "Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating ...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE ... The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart ...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

... (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial for B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma and mantle cell lymphoma. Non-clinical studies were conducted by Sunesis evaluating SNS-032's mechanism of action and in vitro activity against human multiple ...